Historical milestones in the development of tibolone (Livial^®)

References

• Organon, Neth Patent Application 6,406,797 Chem Abstr 64, 12759b (1966)
   Google Scholar
• Van Vliet NP, Broess AIA, Peters JAM, van den Broek JAJ, Leemhuis JAJ, Zeelen FJ. An alternative synthesis of 17β- hydroxy-7α-methyl-19-nor-17α-pregn-5(10)-en-20-yn-3-one (Org OD14). Recl Trav Chim Pays-Bas 1986;105:111–15
   Google Scholar
• Overbeek GA, van Vliet NP, van der Vies J, de Visser J, Crombag FJ, Assendorp R. The influence of steroids on the skeleton. Arch Int Pharmacodyn Ther 1969;182:420
   PubMedGoogle Scholar
• Sandker GW, Vos RM, Delbressine LP, . Metabolism of three pharmacologically active drugs in isolated human and fat hepatocytes: analysis of interspecies variability and comparison with metabolism in vivo. Xenobiotica 1994;24:143–55
   PubMed Web of Science ®Google Scholar
• Tax L, Goorissen EM, Kicovic PM. Clinical profile of Org OD14. Maturitas 1987;Suppl 1:3–13
   PubMed Web of Science ®Google Scholar
• Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP. The in vivo human metabolism of tibolone. Drug Metab Dispos 2002;30:106–12
   PubMed Web of Science ®Google Scholar
• Markiewicz L, Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium. J Steroid Biochem 1990;35:535–41
   PubMedGoogle Scholar
• de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids 2003;68:21–30
   PubMed Web of Science ®Google Scholar
• Lindsay R, Hart DM, Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J 1980;280:1207–9
   PubMed Web of Science ®Google Scholar
• de Visser J, Coert A, Feenstra H, van der Vies J. Endocrinological studies with (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14). Arzneimittelforschung 1984;34:1010–17
   PubMed Web of Science ®Google Scholar
• Jelinek J, Kappen A, Schönbaum E, Lomax P. A primate model of human postmenopausal hot flushes. J Clin Endocrinol Metab 1984;59:1224–8
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Petraglia F, Facchinetti F, . Effects of Org OD 14 on pituitary and peripheral beta-endorphin in castrated rats and post-menopausal women. Maturitas 1987;Suppl 1:35–48
   PubMedGoogle Scholar
• Ederveen AG, Kloosterboer HJ. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J Bone Miner Res 2001;16:1651–7
   PubMed Web of Science ®Google Scholar
• Punnonen R, Liukko P, Cortes-Prieto J, . Multicentre study of effects of Org OD 14 on endometrium, vaginal cytology and cervical mucus in post-menopausal and oophorectomized women. Maturitas 1984;5:281–6
   PubMed Web of Science ®Google Scholar
• Tang B, Markiewicz L, Kloosterboer HJ, Gurpide E. Human endometrial 3 beta-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14). J Steroid Biochem Mol Biol 1993;45:345–51
   PubMed Web of Science ®Google Scholar
• Blom MJ, Wassink MG, De Gooyer ME, . Metabolism of tibolone and its metabolites in uterine and vaginal tissue of rat and human origin. J Steroid Biochem Mol Biol 2006;101:42–9
   PubMed Web of Science ®Google Scholar
• Timmer CJ, Houwing NS. Dose proportionality of three different doses of tibolone. Pharmacotherapy 2002;22:6–13
   PubMed Web of Science ®Google Scholar
• Verheul HA, Timmer CJ, Kloosterboer HJ. Pharmacokinetic parameters of sulfated tibolone metabolites in postmenopausal women after single and multiple doses of tibolone. Clin Pharmacol Ther 2007;81:573–9
   PubMed Web of Science ®Google Scholar
• Kloosterboer HJ, Schoonen WG, Deckers GH, Klijn JG. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol 1994;49:311–18
   PubMed Web of Science ®Google Scholar
• Chetrite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 1997; 17:135–40
   PubMed Web of Science ®Google Scholar
• de Gooyer ME, Overklift Vaupel Kleyn GT, Smits KC, Ederveen AGH, Verheul AM, Kloosterboer HJ. Tibolone: a compound with tissue-specific inhibitory effects on sulfatase. Mol Cell Endocrinol 2001;183;55–62
   PubMed Web of Science ®Google Scholar
• Gompel A, Kandouz M, Siomachkova M, . Effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. Gynecol Endocrinol 1997;11(Suppl 1):77–9
   Google Scholar
• Gompel A, Chaouat M, Jacob D, Perrot JY, Kloosterboer HJ, Rostene W. In vitro studies of tibolone in breast cells. Fertil Steril 2002;78:351–9
   PubMed Web of Science ®Google Scholar
• Colacurci N, Mele D, Franciscis P de, Costa V, Fortunato N, Seta L de. Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol 1998;80:235–8
   PubMed Web of Science ®Google Scholar
• Erel CT, Elter K, Akman C, . Mammographic changes in women receiving tibolone therapy. Fertil Steril 1998;69:870–5
   PubMed Web of Science ®Google Scholar
• Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin Drug Invest 2000;20:101–17
   PubMed Web of Science ®Google Scholar
• Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105:904–11
   PubMedGoogle Scholar
• Nathorst-Böös J, Hammar M. Effect on sexual life – a comparison between tibolone and a continuous estradiol–norethisterone acetate regimen. Maturitas 1997;26:15–20
   PubMed Web of Science ®Google Scholar
• Dören M, Rübig A, Coelingh Bennink HJ, Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999;6:299–306
   PubMed Web of Science ®Google Scholar
• Dören M, Rübig A, Coelingh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75: 554–9
   PubMed Web of Science ®Google Scholar
• Landgren MB, Bennink HJ, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG 2002;109:1109–14
   PubMed Web of Science ®Google Scholar
• Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas 2005;50:222–30
   PubMed Web of Science ®Google Scholar
• Kloosterboer HJ, Ederveen AG. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/−progestogen) treatments. J Steroid Biochem Mol Biol 2003;83:157–65
   Web of Science ®Google Scholar
• Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001;86:4717–26
   PubMed Web of Science ®Google Scholar
• Cline JM, Register TC, Clarkson TB. Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause 2002;9:422–9
   PubMed Web of Science ®Google Scholar
• Conner P, Christow A, Kersemaekers W, . A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen-progestogen treatment. Climacteric 2004;7:50–8
   PubMed Web of Science ®Google Scholar
• Lundström E, Christow A, Kersemaekers W, . Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717–22
   PubMed Web of Science ®Google Scholar
• Valdivia I, Campodónico I, Tapia A, Capetillo M, Espinoza A, Lavín P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004;81: 617–23
   PubMed Web of Science ®Google Scholar
• Kubista E, Planellas Gomez JV, Dowsett M, . Effect of tibolone on breast cancer cell proliferation in postmenopausal ER + patients: results from STEM trial. Clin Cancer Res 2007;3:185–90
   Google Scholar
• Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein(a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 2001;75:898–915
   PubMed Web of Science ®Google Scholar
• Zandberg P, Peters JL, Demacker PN, Smit MJ, de Reeder EG, Meuleman DG. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits. Arterioscler Thromb Vasc Biol 1998;18:1844–54
   PubMed Web of Science ®Google Scholar
• Williams JK, Hall J, Anthony MS, Register TC, Reis SE, Clarkson TB. A comparison of tibolone and hormone replacement therapy on coronary artery and myocardial function in ovariectomized atherosclerotic monkeys. Menopause 2002;9:41–51
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Anthony MS, Clarkson TB, St Clair RW. Serum cholesterol efflux potential in postmenopausal monkeys treated with tibolone or conjugated estrogens. Metabolism 2002;51: 523–30
   PubMed Web of Science ®Google Scholar
• Bots ML, Evans GW, Riley W, . OPAL Investigators. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006;27: 746–55
   PubMed Web of Science ®Google Scholar
• von Eckardstein A, Crook D, Elbers J, . Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux. Clin Endocrinol (Oxf) 2003;58:49–58
   PubMed Web of Science ®Google Scholar
• Simoncini T, Mannella P, Fornari L, . Tibolone activates nitric oxide synthesis in human endothelial cells. J Clin Endocrinol Metab 2004;89:4594–600
   PubMed Web of Science ®Google Scholar
• Dubey RK, Gillespie DG, Grögli M, Kloosterboer HJ, Imthurn B. Tibolone and its metabolites induce antimitogenesis in human coronary artery smooth muscle cells: role of estrogen, progesterone, and androgen receptors. J Clin Endocrinol Metab 2004;89: 852–9
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ettinger B, Delmas PD, .; LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697–708
   PubMed Web of Science ®Google Scholar
• Steckelbroeck S, Jin Y, Oyesanmi B, Kloosterboer HJ, Penning TM. Tibolone is metabolized by the 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four human isozymes of the aldo-keto reductase 1C subfamily: inversion of stereospecificity with a delta5(10)-3-ketosteroid. Mol Pharmacol 2004;66:1702–11
   PubMed Web of Science ®Google Scholar
• Falany JL, Macrina N, Falany CN. Sulfation of tibolone and tibolone metabolites by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol 2004;88:383–91
   PubMed Web of Science ®Google Scholar
• Falany JL, Falany CN. Regulation of SULT1E1 expression in Ishikawa adenocarcinoma cells by tibolone. Steroids 2006;71: 880–5
   PubMed Web of Science ®Google Scholar
• Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 2004;48(Suppl 1):S30–40
   PubMedGoogle Scholar
• Reed MJ, Kloosterboer HJ. Tibolone: a selective tissue estrogenic activity regulator (STEAR). Maturitas 2004;48(Suppl 1):S4–6
   PubMedGoogle Scholar
• Clarkson TB, Anthony MS, Cline JM, Lees CJ, Ederveen AG. Multisystem evaluations of the long-term effects of tibolone on postmenopausal monkeys. Maturitas 2004;48(Suppl 1): S24–9
   PubMed Web of Science ®Google Scholar
• Kenemans P. Tibolone: how does its mechanism of action translate into clinical effects? Maturitas 2004;48 (Suppl 1): S1–3
   PubMedGoogle Scholar
• Verheul HA, Timmer CJ, van Iersel ML, Delbressine LP, Kloosterboer HJ. Pharmacokinetic parameters of tibolone and metabolites in plasma, urine, feces, and bile from ovariectomized cynomolgus monkeys after a single dose or multiple doses of tibolone. Drug Metab Dispos 2007;35:1112–18
   PubMed Web of Science ®Google Scholar
• Verheul HA, van Iersel ML, Delbressine LP, Kloosterboer HJ. Selective tissue distribution of tibolone metabolites in mature ovariectomized female cynomolgus monkeys after multiple doses of tibolone. Drug Metab Dispos 2007;35:1105–11
   PubMed Web of Science ®Google Scholar
• Kloosterboer HJ, Löfgren L, von Schoulz E, von Schoultz B, Verheul HA. Estrogen and tibolone metabolite levels in blood and breast tissue of postmenopausal women recently diagnosed with early-stage breast cancer and treated with tibolone or placebo for 14 days. Reprod Sci 2007;4:51–9
   Google Scholar
• Verheul HA, Blok LJ, Burger CW, Hanifi-Moghaddam P, Kloosterboer HJ. Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate. Reprod Sci 2007;14:160–8
   PubMed Web of Science ®Google Scholar
• Völker W, Coelingh Bennink HJ, Helmond FA. Effects of tibolone on the endometrium. Climacteric 2001;4:203–8
   PubMedGoogle Scholar
• Archer DF, Hendrix S, Gallagher JC, . Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911–18
   PubMed Web of Science ®Google Scholar
• Ettinger B, Kenemans P, Johnson SR, . Endometrial effects of tibolone in elderly, osteoporotic women. Obstet Gynecol 2008;112:653–9
   PubMed Web of Science ®Google Scholar
• Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med 2009;151: 703–15, W-226–35
   PubMed Web of Science ®Google Scholar
• Kenemans P, Bundred NJ, Foidart JM, . LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135–46
   PubMed Web of Science ®Google Scholar